News >

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

Jason M. Broderick @jasoncology
Published: Wednesday, Nov 07, 2018

John P. Leonard, MD

John P. Leonard, MD

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explained John P. Leonard, MD, in a session at the 36th Annual CFS®.

Leonard, associate dean for Clinical Research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian Hospital, provided expert insight on the latest advances in both the induction and relapsed/refractory setting.

Maintenance Therapy

Standard induction approaches for advanced-stage follicular lymphoma include the chemoimmunotherapy regimens of rituximab (Rituxan) combined with CHOP (R-CHOP), CVP (R-CVP), or bendamustine (BR). Researchers have attempted to build on the success of these regimens through maintenance therapy.

“This has led to, again, to some using obinutuzumab in this setting because of the PFS benefit. Others have said, again, ‘Well without an overall survival benefit and with the commitment based on this study to use maintenance, perhaps sticking with rituximab is just fine. So, there are differences in practice, in this regard.’”

Chemotherapy-Free Approach

Leonard explained that, “to the extent that lenalidomide (Revlimid) is not chemotherapy,” another novel upfront strategy is implementing a “chemotherapy-free approach” by replacing chemotherapy with lenalidomide in standard regimens.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication